Last reviewed · How we verify

NCT05382403: NOVIC

Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage

Recruiting now NA Last updated 21 December 2023
What this trial tests

NA trial testing Jada® System in Postpartum Hemorrhage in 424 participants. Currently enrolling.

Timeline
23 October 2023
Primary endpoint
31 August 2026
30 April 2027

Quick facts

Lead sponsorWomen and Infants Hospital of Rhode Island
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment424
Start date23 October 2023
Primary completion31 August 2026
Estimated completion30 April 2027
Sites2 locations across Ghana

Drugs / interventions tested

Conditions studied

Sponsor

Women and Infants Hospital of Rhode Island

Who can join

Adults 18 to 44, female only, with Postpartum Hemorrhage or Maternal Death. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This will be the first, definitive, randomized control trial (N=424) to test the hypothesis that the Jada® System is effective, safe and cost-effective in treating PPH, compared to standard care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Jada® System

Trials testing the same drug.

Other recruiting trials for Postpartum Hemorrhage

Currently open trials in the same condition.

Other Women and Infants Hospital of Rhode Island trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05382403.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing